Clinical Trial

NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL

Study acronym: POTENTIAL-P
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated December 17, 2024 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
An Open, Single treatment arm, Multi-center, Prospective, Phase 2 Trial to Evaluate Efficacy and Safety of NB02 (Poseltinib) combined with Rituximab and Lenalidomide as a Salvage Therapy for Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma
Trial Details
NCT Number NCT06737250
Lead Sponsor NOBO Medicine
Conditions Primary CNS Lymphoma (PCNSL)
Enrollment 33 participants
Start Date 2024-11-25
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-17